Tardive Dyskinesia: Etiology, Treatment (Movement Disorders Congress 2002)

Subject: Tardive Dyskinesia: Etiology, Treatment (Movement Disorders Congress 2002)

Date: 11/19/2002

E-MOVE reports from the Seventh International Congress of Parkinson’s Disease and Movement Disorders, November 10-14 in Miami, Florida. Poster (P), platform session (PL), and page numbers are from Movement Disorders 2002;17(suppl 5).

1. Remote methamphetamine abuse as a potential cause of tardive dyskinesia: A report of 5 cases
P Hogarth
P1089; S329

Five patients with dyskinesias reported amphetamine use from 6 months to 4 years before examination. Patients had no prior use of neuroleptics, and neuroimaging and lab studies revealed no other cause of the movement disorder. The author states, “This study provides clinical correlation to recent functional neuroimaging studies documenting long-term changes in dopamine transporter systems in the basal ganglia of detoxified methamphetamine abusers and suggests that methamphetamine may be a cause of tardive dyskinesia."

2. Olanzapine improves tardive dyskinesia in patients with schizophrenia: Results of a controlled prospective study
BJ Kinon, VL Stauffer, L Wang, KT Thi, S Kollack-Walker
P1086; S329

Olanzapine reduces symptoms of tardive dyskinesia, according to this study.

Ninety-five patients with TD of at least moderate severity received up to 20 mg/day olanzapine after tapering of other antipsychotic medications and a two-week washout. Patients were blindly randomized to undergo either dose maintenance or a two-week, 75% dose reduction period within the 32-week treatment period.

Fifty-eight percent of patients completed the study; 10% withdrew due to inadequate control of psychiatric symptoms and 8% for adverse events. Olanzapine led to an approximately 50% reduction in Abnormal Involuntary Treatment Scale scores. AIMS scores did not worsen during the dose-reduction period.

Supported by Eli Lilly.

3. Complete cessation of orofacial dyskinesias with bilateral internal pallidal stimulation in a 39-year-old woman with tardive dyskinesia
C van der Linden, H Colle, E Foncke, G Alessi, D Rijckaert, L De Waele
P1080; S327

The authors present a case report of successful treatment of TD of 4 years’ duration, which was only partially responsive to high-dose medication. They report, “Two days following surgery all abnormal movements were absent.”
----

2002 E-MOVE conference reports are made possible in part through unrestricted educational grants from these sponsors:
Gold Level: Bertek Pharmaceuticals, Elan Pharmaceuticals, Pharmacia Corporation.
Silver Level: GlaxoSmithKline, Amarin Pharmaceuticals
Bronze Level: Procter & Gamble Pharmaceuticals, Schwarz Pharma.

E-MOVE Editor: Richard Robinson, NASW, WE MOVE